(Q44769706)

6 December 2017

title

Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy (English)

1 reference

6 December 2017

1 reference

1

Tomasz M Beer

1 reference

6 December 2017

Mark Garzotto

2

1 reference

6 December 2017

Kristi M Eilers

series ordinal

3

1 reference

6 December 2017

Dianne Lemmon

series ordinal

4

1 reference

6 December 2017

Emily M Wersinger

series ordinal

5

1 reference

6 December 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

6 December 2017

1 reference

6 December 2017

volume

63

1 reference

6 December 2017

issue

2

1 reference

6 December 2017

page(s)

342-347

1 reference

Coexpression of gonadotropic hormones and their corresponding FSH- and LH/CG-receptors in the human prostate

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.045

Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.045

Prostate—an extrapituitary source of follicle-stimulating hormone (FSH): Occurrence, localization, and de novo biosynthesis and its hormonal modulation in primates and rodents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.045

Immunocytochemical localisation of follicle stimulating hormone (FSH) in normal, benign and malignant human prostates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.045

Prolactin and pituitary gonadotropin values and responses to acute luteinizing hormone-releasing hormone (LHRH) challenge in patients having long-term treatment with a depot LHRH analogue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.045

An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.045

Hormonal pattern in prostatic carcinoma following orchidectomy: 5-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.045

Serum bioactive and immunoreactive follicle-stimulating hormone in prostatic cancer patients during gonadotropin-releasing hormone agonist treatment and after orchidectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.045

The Effects of Orchidectomy, Estrogens, and Cyproterone Acetate on Plasma Testosterone, LH, and FSH Concentrations in Patients with Carcinoma of the Prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.045

Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.045

A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.045

Effects of intravenous administration of high dose-diethylstilbestrol diphosphate on serum hormonal levels in patients with hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.045

Stronger suppression of serum testosterone and FSH levels by a synthetic estrogen than by castration or an LH-RH agonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.045

Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.045

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.045

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.045

Optimal two-stage designs for phase II clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.045

Expression of gonadotropin-releasing hormone (GnRH) and GnRH receptor mRNA in prostate cancer cells and effect of GnRH on the proliferation of prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.045

Signalling and anti-proliferative effects mediated by gonadotrophin-releasing hormone receptors after expression in prostate cancer cells using recombinant adenovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.045

Expression of luteinizing hormone/human chorionic gonadotropin receptor gene in benign prostatic hyperplasia and in prostate carcinoma in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.045

10.1016/J.UROLOGY.2003.09.045

7 January 2021

Identifiers

DOI

1 reference

6 December 2017

1 reference